(Q36613906)

15 August 2017

1 reference

title

Disease-modifying drugs for multiple sclerosis: current and future aspects (English)

1 reference

15 August 2017

0 references

Mark S Freedman

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7 Suppl 1

1 reference

15 August 2017

page(s)

S1-9

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

15 August 2017

1 reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Western vs optic-spinal MS: two diseases, one treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Suppression of demyelination by mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Diagnosis and treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Axonal degeneration and progressive neurologic disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

The importance of maintaining effective therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Cladribine: a review of its use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Cladribine for multiple sclerosis: review and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Cervical cord atrophy assessment on magnetic resonance imaging: PROMiSe trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Neuroprotection in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Pharmacogenetics of autoimmune diseases: research issues in the case of Multiple Sclerosis and the role of IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.1.S1

21 January 2018

Identifiers

DOI

10.1517/14656566.7.1.S1

1 reference

15 August 2017

1 reference